Pembrolizumab plus AVD for classical Hodgkin lymphoma, targeting the CD40/CD40-ligand axis in Waldenström Macroglobulinemia, and CXCR4-expressing CAR-cytokine induced killer cells in AML
Blood Podcast
00:00
The Safety and Tolerability of Pembrolysumab Therapy
Intervenous pembrolysmab 200 mg was given every 21 days, starting on cycle 1, day 1. Grade 3 to 4 non-hematologic adverse events were seen in 12 patients. Efficacy analysis performed on 29 responsive-aluable patients revealed an overall response rate of 100%.
Transcript
Play full episode
